Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal

p21-Activated Kinase 1 Coordinates Aberrant Cell Survival and Pericellular Proteolysis in a Three-Dimensional Culture Model for Premalignant Progression of Human Breast Cancer

(2015) Quanwen Li et al.   NEOPLASIA

Circadian and Melatonin Disruption by Exposure to Light at Night Drives Intrinsic Resistance to Tamoxifen Therapy in Breast Cancer

(2014) R. T. Dauchy et al.   CANCER RESEARCH

The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy

(2014) Eilin Austreid et al.   EXPERT OPINION ON PHARMACOTHERAPY

Light Exposure at Night Disrupts Host/Cancer Circadian Regulatory Dynamics: Impact on the Warburg Effect, Lipid Signaling and Tumor Growth Prevention

(2014) David E. Blask et al.   PLoS One

Genetic Interactions of STAT3 and Anticancer Drug Development

(2014) Bingliang Fang   Cancers

Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells

(2013) V Martín et al.   BRITISH JOURNAL OF CANCER

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

(2013) Howard A. Burris   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Combined Targeting of PDK1 and EGFR Triggers Regression of Glioblastoma by Reversing the Warburg Effect

(2013) K. K. Velpula et al.   CANCER RESEARCH

Preventive Effects of Ellagic Acid Against Doxorubicin-Induced Cardio-Toxicity in Mice

(2013) Ming-cheng Lin et al.   Cardiovascular Toxicology

A Novel Insight into the Cardiotoxicity of Antineoplastic Drug Doxorubicin

(2013) Zbynek Heger et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin

(2013) Diana Tavares-Valente et al.   JOURNAL OF BIOENERGETICS AND BIOMEMBRANES

The ErbB/HER family of protein-tyrosine kinases and cancer

(2013) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Imatinib Reverses Doxorubicin Resistance by Affecting Activation of STAT3-Dependent NF-κB and HSP27/p38/AKT Pathways and by Inhibiting ABCB1

(2013) Jonathan T. Sims et al.   PLoS One

p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model

(2012) H. Y. Chow et al.   CANCER RESEARCH

Chemotherapy-Resistant Metastatic Breast Cancer

(2012) Carrie Marquette et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart

(2012) Giannoula L. Klement et al.   Frontiers in Pharmacology

Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells

(2011) W. Zhang et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Regulation and function of the RSK family of protein kinases

(2011) Yves Romeo et al.   BIOCHEMICAL JOURNAL

Melatonin and Associated Signaling Pathways that Control Normal Breast Epithelium and Breast Cancer

(2011) Steven M. Hill et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Involvement of PKC delta (PKCδ) in the resistance against different doxorubicin analogs

(2010) María Ines Díaz Bessone et al.   BREAST CANCER RESEARCH AND TREATMENT

Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

(2008) Suman Lal et al.   CANCER SCIENCE

Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver

(2008) N. Kassner et al.   DRUG METABOLISM AND DISPOSITION

Switching of G-protein Usage by the Calcium-sensing Receptor Reverses Its Effect on Parathyroid Hormone-related Protein Secretion in NormalVersusMalignant Breast Cells

(2008) Ramanaiah Mamillapalli et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Scaffolding function of PAK in the PDK1–Akt pathway

(2008) Maiko Higuchi et al.   NATURE CELL BIOLOGY

Inactivation of the anticancer drugs doxorubicin and oracin by aldo–keto reductase (AKR) 1C3

(2008) Romana Novotna et al.   TOXICOLOGY LETTERS